University of California Davis Health
Welcome,         Profile    Billing    Logout  
 40 Trials 
101 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Valicenti, Richard K
INNOVATE, NCT04134260: Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

Recruiting
3
586
US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Hormone Therapy, Chemotherapy-Hormones/Steroids, Endocrine Therapy, Hormonal Therapy, hormone treatment, Hormones, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
11/26
11/26
SHIELD-RT, NCT03775265: Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Active, not recruiting
3
475
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy of Bladder, Bladder Biopsy, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cystoscopy, CS, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mitomycin, Ametycine, Jelmyto, MITO, Mito-C, Mito-Medac, Mitocin, Mitocin-C, Mitolem, Mitomycin C, Mitomycin pyelocalyceal, Mitomycin-C, Mitomycin-X, Mitomycine C, Mitosol, Mitozytrex, Mutamycin, Mutamycine, NCI-C04706, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Survey Administration, Transurethral Resection of Bladder Tumor, Transurethral resection (TURBT), TURBT
National Cancer Institute (NCI)
Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
06/27
06/27
S1802, NCT03678025: Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Recruiting
3
1273
Europe, US, RoW
Abiraterone, CB 7598, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Degarelix, FE200486, Firmagon, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, SCH 13521, Tafenil, Tecnoflut, Testotard, Goserelin Acetate, ZDX, Zoladex, Histrelin Acetate, Supprelin, Vantas, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Nilutamide, Anandron, Nilandron, RU-23908, Orchiectomy, Castration, Male Castration, Male Gonadectomy, orchidectomy, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, Radical Prostatectomy, Prostatovesiculectomy, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Decapeptyl, Detryptoreline
SWOG Cancer Research Network, National Cancer Institute (NCI)
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
04/28
10/31
GUIDANCE, NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Recruiting
3
2050
Canada, US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma
04/32
04/37
PREDICT-RT, NCT04513717: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The Trial

Recruiting
3
2478
Canada, US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
12/33
12/33
NADIR, NCT04037254: Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer

Active, not recruiting
2
22
Canada, US
Gonadotrophin Releasing Hormone, AY-24031, D-His-6-Pro-8-NEt-LHRH, Follicle Stimulating Hormone-Releasing Factor, GN-RH, GnRH, Gonadoliberin, Gonadorelin, Gonadorelinum, gonadotropin-releasing hormone, Hoe- 471, LH-RF, LH-RH, LH/FSH-RF, LH/FSH-RH, LHRH, Luliberin, Luteinising Hormone-Releasing Factor, Luteinizing Hormone-Releasing Factor, luteinizing hormone-releasing hormone, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Niraparib, MK-4827, MK4827
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
07/24
08/26
Bowlus, Christopher L
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study

Recruiting
3
251
Europe, Canada, Japan, US, RoW
Linerixibat
GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Cholestasis
02/27
02/27
SHIP, NCT03561584: Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

Recruiting
2
42
US
Sulfasalazine, Azulfidine, Placebo
Brigham and Women's Hospital
Primary Sclerosing Cholangitis
09/24
11/24
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Primary Biliary Cholangitis
11/24
02/25
SPRING, NCT04595825 / 2019-002945-39: CM-101 in PSC Patients -The Study

Active, not recruiting
2
68
Europe, US, RoW
Anti-human CCL24 monoclonal antibody (CM-101), Placebo
ChemomAb Ltd., ChemomAb Ltd
Primary Sclerosing Cholangitis
09/24
09/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

Not yet recruiting
2
87
US
LB-P8 low-dose, LB-P8 high-dose, Placebo
LISCure Biosciences
Primary Sclerosing Cholangitis (PSC)
03/28
02/29
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
271
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
12/25
03/26
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis

Active, not recruiting
1/2
42
US
CNP-104, Placebo
COUR Pharmaceutical Development Company, Inc.
Primary Biliary Cholangitis
01/26
01/26
Sood, Namita
ARTISAN, NCT05203510: A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Recruiting
4
50
US
Parenteral Treprostinil, Remodulin, Oral Treprostinil, Orenitram
United Therapeutics, Lung Biotechnology PBC
Pulmonary Arterial Hypertension
12/25
12/27
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
IMPAHCT-FUL, NCT05557942 / 2021-006864-25: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension

Terminated
3
186
Europe, Canada, US, RoW
AV-101
Aerovate Therapeutics, Aerovate Therapeutics Inc
Pulmonary Arterial Hypertension
08/24
08/24
NCT05983250: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Recruiting
3
152
Canada, US
TNX-103, Placebo
Tenax Therapeutics, Inc., Medpace, Inc., Northwestern University
Pulmonary Hypertension
03/27
07/27
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
ELEVATE 2, NCT04712669 / 2020-004971-42: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension

Completed
2
108
Europe, Canada, US, RoW
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Altavant Sciences GmbH
Pulmonary Arterial Hypertension
06/23
08/23
ASCENT, NCT06129240: An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

Recruiting
N/A
60
US
LIQ861
Liquidia Technologies, Inc.
Pulmonary Hypertension, Interstitial Lung Disease
07/26
10/26
PREDICT-HP, NCT04844359: A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis

Recruiting
N/A
135
US
National Jewish Health, University of California, Davis, Mayo Clinic, University of Chicago, University of Texas Southwestern Medical Center, University of Arizona, University of Utah
Hypersensitivity Pneumonitis
01/25
01/26
IPF-PRO, NCT01915511: Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Checkmark
Oct 2015 - Oct 2015: 
Recruiting
N/A
3000
US
Duke University, Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
01/28
01/28
Lopez, Amanda
Senergy-CKD, NCT04984226: Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD

Recruiting
2
80
US
Sodium bicarbonate, placebo
University of California, Davis, Vanderbilt University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Diseases, Metabolic Acidosis, Fatigue, Physical Endurance, Insulin Resistance, Mitochondrial Energetics, Diabetes
12/25
07/26
Abedi, Mehrdad
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Terminated
3
130
US
AB-205, E-CEL cells, Placebo
Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
Hodgkin Lymphoma, Non Hodgkin Lymphoma
12/23
01/25
GRASP, NCT05353647: A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (, BMT CTN 2001)

Active, not recruiting
2
25
US
Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
David Williams, National Heart, Lung, and Blood Institute (NHLBI), California Institute for Regenerative Medicine (CIRM), bluebird bio, Blood and Marrow Transplant Clinical Trials Network
Sickle Cell Disease
05/26
05/26
EBVision, NCT04554914 / 2020-000177-25: A Study to Evaluate Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases

Hourglass Jan 2023 - Dec 2023 : From P2 trial for Epstein-Barr virus-associated sarcoma
Recruiting
2
190
Europe, US
Tabelecleucel, tab-cel®, ATA129, EBV-CTLs
Atara Biotherapeutics
Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
06/27
05/29
NCT02797470: Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Active, not recruiting
1/2
11
US
Autologous Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Carmustine, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, Gliadel, N,N'-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, SK 27702, SRI 1720, WR-139021, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Laboratory Biomarker Analysis, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplantation
AIDS Malignancy Consortium, National Cancer Institute (NCI), California Institute for Regenerative Medicine (CIRM)
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Follicular Lymphoma, Stage III Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
05/21
06/25
Starlight-1, NCT06343311: T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Recruiting
1/2
21
US
EB103
Estrella Biopharma, Inc., Eureka Therapeutics Inc.
B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, HIV Associated Lymphoma, CNS Lymphoma, High-grade B-cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
12/26
12/27
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Hourglass Jul 2024 - Dec 2024 : Submission in UK for adult r/r B-ALL
Active, not recruiting
1/2
153
NA
AUTO1, Obecabtagene autoleucel (obe-cel)
Autolus Limited
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
05/25
05/25
NCT04648046: CAR-T Cells for HIV Infection

Recruiting
1/2
18
US
Cyclophosphamide, LVgp120duoCAR-T cells, low dose, LVgp120duoCAR-T cells, high dose, Analytic Treatment Interruption
Steven Deeks, Caring Cross
HIV Infections
12/27
12/28
LIMBER-TREG108, NCT05423691: Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Recruiting
1
24
US
CK0804
Cellenkos, Inc.
Myelofibrosis
04/24
04/24
BMSCRP1, NCT04925687: Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa

Completed
1
4
US
Intravitreal autologous CD34+ cells
University of California, Davis, Cures Within Reach, The Retina Society
Retinitis Pigmentosa
11/23
11/23
OGFT001-001, NCT03802695: A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Recruiting
1
186
US
OrcaGraft (Orca-Q)
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia
04/26
04/28
NCT05052528: Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting
1
36
US
Chimeric Antigen Receptor T-Cell Therapy, CAR T Infusion, CAR T Therapy, CAR T-cell Therapy, Chimeric Antigen Receptor T-cell Infusion, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
Mehrdad Abedi, MD, National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
05/25
12/25
NEXICART-2, NCT06097832: Study of NXC-201 CAR-T in Patients with Light Chain (AL) Amyloidosis

Recruiting
1
40
US
NXC-201 CAR-T, HBI0101 CAR-T
Nexcella Inc., Immix Biopharma, Inc.
Light Chain (AL) Amyloidosis
12/26
01/39
NCT04422912: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Recruiting
1
55
US
DSG3-CAART or CABA-201
Cabaletta Bio
Pemphigus Vulgaris
01/29
01/29
Dossett, Michelle
NCT05415735: Stress Management and Resiliency Training Following Acute Myocardial Infarction

Completed
N/A
10
US
Stress Management and Resiliency Training Program
University of California, Davis
Heart Attack, Cardiovascular Diseases
12/22
10/23
NCT05675995: Qigong for Post Acute Sequelae of COVID-19 Infection

Completed
N/A
40
US
External Qigong
University of California, Davis
Long COVID
05/24
05/24
NCT06574191: The Effects of Patient and Visit Characteristics on Health Outcomes in Knee Osteoarthritis

Not yet recruiting
N/A
220
US
Topical Diclofenac gel 1%
University of California, Davis, National Institute on Aging (NIA), Beth Israel Deaconess Medical Center
Knee Osteoarthritis
08/27
10/27
Roshanravan, Baback
NCT05422534: CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease

Recruiting
3
156
US
CoQ10, ubiquinone, Placebo, inactive substance, HB-HIIT, exercise, Observational, Normal Routine
Vanderbilt University Medical Center, University of California, Davis
End Stage Renal Disease
06/27
10/27
ESTEEM-CKD, NCT02923063: Exercise Study Testing Enhanced Energetics of Mitochondria Video Integrated Delivery of Activity Training in CKD

Active, not recruiting
2
32
US
Combined Aerobic and Resistance Exercise via videoconferencing
University of California, Davis
Moderate-severe Chronic Kidney Disease Not Treated With Dialysis, Diabetic Kidney Disease, HgbA1c Less Than 8.5
10/24
12/24
Senergy-CKD, NCT04984226: Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD

Recruiting
2
80
US
Sodium bicarbonate, placebo
University of California, Davis, Vanderbilt University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Diseases, Metabolic Acidosis, Fatigue, Physical Endurance, Insulin Resistance, Mitochondrial Energetics, Diabetes
12/25
07/26
Allen, Roblee
PHAR, NCT04071327: Pulmonary Hypertension Association Registry

Recruiting
N/A
3000
US
Pulmonary Hypertension Association, Inc., University of Washington, the Collaborative Health Studies Coordinating Center
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
10/25
10/25
Painting, Lynda
GuideView, NCT04838626 / 2020-003958-67: Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

Completed
2/3
195
Europe, US
[18F]CTT1057, Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
Novartis Pharmaceuticals
Prostatic Neoplasms, Prostate Cancer
11/23
11/23
NCT06453915: NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease

Not yet recruiting
1
12
US
18F-DPA-714, 18F-FDG
University of California, Davis
Positron Emission Tomography
07/26
07/27
NCT05876858: EXPLORER Total Body PET/CT Imaging for Myofascial Pain

Recruiting
1
53
US
18F-FDG, 11C-butanol
University of California, Davis, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH)
Myofascial Pain
09/25
09/26
NCT06014515: Single-tracer Multiparametric PET Imaging

Recruiting
1
60
US
18F-FDG, 11C-butanol
University of California, Davis, National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Healthy Subjects, Cardiovascular Disease
08/28
08/33
NCT04020978: Parametric PET of Genitourinary Cancer

Completed
N/A
11
US
Parametric PET/CT
University of California, Davis
Genitourinary Cancer
01/23
12/23
NCT05625217: Total-Body FDG PET for Radiotherapy Response Assessment in Head and Neck Cancer

Completed
N/A
7
US
Total Body PET/CT Imagin
University of California, Davis, National Cancer Institute (NCI)
Head and Neck Cancer
11/24
11/24
Perry-Baker, Cynthia L
PHAR, NCT04071327: Pulmonary Hypertension Association Registry

Recruiting
N/A
3000
US
Pulmonary Hypertension Association, Inc., University of Washington, the Collaborative Health Studies Coordinating Center
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
10/25
10/25
Dhaliwal, Sandeep
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
SHIP, NCT03561584: Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

Recruiting
2
42
US
Sulfasalazine, Azulfidine, Placebo
Brigham and Women's Hospital
Primary Sclerosing Cholangitis
09/24
11/24
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
GATEWAY, NCT04537377 / 2020-000963-22: A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease

Active, not recruiting
1/2
4
Europe, US
VTX-801
Vivet Therapeutics SAS
Wilson's Disease
12/24
06/29
EXPLORER, NCT04165343: Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on

Completed
N/A
81
US
Positron Emission Tomography (PET) on EXPLORER, PET Scan, Magnetic Resonance Imaging, MRI, Echocardiogram and Electrocardiogram, Echo and EKG or ECG, Blood test, Lab test
University of California, Davis
Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
05/23
05/23
NCT03560037: Use of a Distal Colonoscope Attachment to Increase Detection of Sessile Serrated Adenomas

Completed
N/A
427
US
Endocuff Vision Assisted Colonoscopy
University of California, Davis
Sessile Serrated Adenoma
12/23
12/23
NCT02754037: Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study

Active, not recruiting
N/A
120
US
Fluorodeoxyglucose (FDG) positron emission tomography (PET), Magnetic resonance imaging (MRI), Magnetic resonance proton density fat fraction (MR-PDFF), Magnetic resonance elastography (MRE), PET Explorer
University of California, Davis, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
06/25
06/25
TARGET-HCC, NCT02954094: A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Recruiting
N/A
10000
Europe, US
Target PharmaSolutions, Inc.
Hepatocellular Cancer
10/25
10/25
TARGET-IBD, NCT03251118: A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

Recruiting
N/A
15000
US
Target PharmaSolutions, Inc.
Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
10/25
10/25
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Recruiting
N/A
5000
Canada, US
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Target PharmaSolutions, Inc.
Hepatitis B, Hepatitis, Liver Diseases
01/26
01/26
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Recruiting
N/A
15000
Europe, US
Target PharmaSolutions, Inc.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
07/36
07/36
Garcia, Omar Felipe Duenas
NCT05664633: The Role of Sugammadex in Posotoperative Urinary Retention in Patients Undergoing Pelvic Floor Reconstructive Procedures

Recruiting
1/2
80
US
Sugammadex
West Virginia University
Postoperative Urinary Retention
06/24
06/24
NCT04881656: Evaluating the Impact of Telehealth-Based ASD Assessments and Supports on Child and Caregiver Outcomes

Active, not recruiting
N/A
80
US
Help is in Your Hands, HIIYH
University of California, Davis, National Center for Advancing Translational Sciences (NCATS)
Autism Spectrum Disorder
06/25
05/33
Jones, Laura M
PROSPECT, NCT04779684: Promoting Self-determination for Institutionalized Older People Without Decision-making Capacity: Advance Care Planning by Proxy

Completed
N/A
20
Europe
Advance care planning by proxy for health care proxies of people without medical decision making capacity
Ralf J. Jox
Advanced Dementia, Loss of Medical Decision Making Capacity
10/23
10/23
NCT04109027: Strengthening Neuro-Cognitive Skills for Success in School, Work and Beyond

Recruiting
N/A
120
US
BrainStrong-GSR, Goal-directed State Regulation Training (GSR), BrainStrong-OPT, Optimization of Brain Functioning (OPT)
VA Office of Research and Development
TBI, Cognitive Dysfunction
09/25
10/25
Cohen, Stuart
DECREASE SSI, NCT05586776: Decolonization to Reduce After-Surgery Events of Surgical Site Infection

Recruiting
4
2700
US
4% Chlorhexidine Gluconate, 2% Mupirocin, Soap Without Antiseptic Properties (Placebo), Placebo Nasal Ointment
University of California, Irvine, University of California, Davis, University of California, San Francisco, University of Massachusetts, Amherst, Hoag Memorial Hospital Presbyterian
Surgical Site Infection
12/27
12/28
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Recruiting
3
274
Europe, US, RoW
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Ansun Biopharma, Inc.
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
08/25
08/25
Diebel, Elizabeth
NCT03904147: TRILUMINATE Pivotal Trial

Active, not recruiting
N/A
572
Europe, Canada, US
TriClipTM Device
Abbott Medical Devices
Tricuspid Regurgitation
11/22
04/29
AIM HIGHer, NCT05064709: Assessment of CCM in HF with Higher Ejection Fraction

Recruiting
N/A
1500
US
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, CCM Group (CCM ON), OPTIMIZER™ Smart Mini System, Sham Group (CCM OFF)
Impulse Dynamics
Heart Failure, Heart Failure with Preserved Ejection Fraction, Heart Failure with Mid Range Ejection Fraction, Heart Failure with Moderately Reduced Ejection Fraction, Diastolic Heart Failure
02/25
02/26
Nardo, Lorenzo
GuidePath, NCT04838613 / 2020-003959-16: Study of Diagnostic Performance of [18F]CTT1057 in BCR

Completed
3
180
Europe, US
[18F]CTT1057, [68Ga]Ga-PSMA-11
Novartis Pharmaceuticals, Novartis Pharma AG
Prostatic Neoplasms, Prostate Cancer, Recurrence
11/23
11/23
GuideView, NCT04838626 / 2020-003958-67: Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

Completed
2/3
195
Europe, US
[18F]CTT1057, Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
Novartis Pharmaceuticals
Prostatic Neoplasms, Prostate Cancer
11/23
11/23
NCT05876858: EXPLORER Total Body PET/CT Imaging for Myofascial Pain

Recruiting
1
53
US
18F-FDG, 11C-butanol
University of California, Davis, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH)
Myofascial Pain
09/25
09/26
NCT04020978: Parametric PET of Genitourinary Cancer

Completed
N/A
11
US
Parametric PET/CT
University of California, Davis
Genitourinary Cancer
01/23
12/23
NCT04110743: EXPLORER PET/CT in Healthy Volunteers

Completed
N/A
30
US
EXPLORER PET/CT
University of California, Davis
Healthy
02/20
02/20
EXPLLN21-01, NCT05160480: A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

Enrolling by invitation
N/A
9
US
Total-body PET imaging
University of California, Davis, Lantheus Medical Imaging
Prostate Cancer, Breast Cancer, Neuroendocrine Tumors
09/25
03/26
NCT04478318: Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma

Enrolling by invitation
N/A
180
US
uEXPLORER/mCT, mCT/uEXPLORER
University of California, Davis
Lung Neoplasm, Lymphoma, Melanoma, Fluorodeoxyglucose, Positron-emission Tomography
06/25
06/25
Gutierrez, Haydee
AIM HIGHer, NCT05064709: Assessment of CCM in HF with Higher Ejection Fraction

Recruiting
N/A
1500
US
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, CCM Group (CCM ON), OPTIMIZER™ Smart Mini System, Sham Group (CCM OFF)
Impulse Dynamics
Heart Failure, Heart Failure with Preserved Ejection Fraction, Heart Failure with Mid Range Ejection Fraction, Heart Failure with Moderately Reduced Ejection Fraction, Diastolic Heart Failure
02/25
02/26
Talbott, Meagan
NCT04881656: Evaluating the Impact of Telehealth-Based ASD Assessments and Supports on Child and Caregiver Outcomes

Active, not recruiting
N/A
80
US
Help is in Your Hands, HIIYH
University of California, Davis, National Center for Advancing Translational Sciences (NCATS)
Autism Spectrum Disorder
06/25
05/33
Nguyen, Jessica N
ABAGART, NCT04474847: Abatacept for the Treatment of Giant Cell Arteritis

Recruiting
3
78
Canada, US
Abatacept, CTLA4-Ig, Orencia, Placebo
University of Pennsylvania
Giant Cell Arteritis
12/29
12/29
NCT04929951: The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis

Recruiting
1
48
US
Micro Fragmented Adipose Tissue, MFAT, Corticosteroid injection
Stanford University
Osteoarthritis Shoulder, Shoulder Pain
12/25
12/25
HEALICOIL_KNTL, NCT04552119: Safety of Treatment of Shoulder Repair

Active, not recruiting
N/A
160
US
HEALICOIL Knotless PEEK, HEALICOIL Knotless REGENESORB
Smith & Nephew, Inc.
Rotator Cuff
08/24
12/24
AIM HIGHer, NCT05064709: Assessment of CCM in HF with Higher Ejection Fraction

Recruiting
N/A
1500
US
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, CCM Group (CCM ON), OPTIMIZER™ Smart Mini System, Sham Group (CCM OFF)
Impulse Dynamics
Heart Failure, Heart Failure with Preserved Ejection Fraction, Heart Failure with Mid Range Ejection Fraction, Heart Failure with Moderately Reduced Ejection Fraction, Diastolic Heart Failure
02/25
02/26
Golez, Jerica
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis

Recruiting
3
150
US, RoW
Saroglitazar Magnesium 1 mg
Zydus Therapeutics Inc.
Primary Biliary Cholangitis
04/27
07/27
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis

Active, not recruiting
1/2
42
US
CNP-104, Placebo
COUR Pharmaceutical Development Company, Inc.
Primary Biliary Cholangitis
01/26
01/26
Portillo, Geraldine
NCT05422534: CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease

Recruiting
3
156
US
CoQ10, ubiquinone, Placebo, inactive substance, HB-HIIT, exercise, Observational, Normal Routine
Vanderbilt University Medical Center, University of California, Davis
End Stage Renal Disease
06/27
10/27
Senergy-CKD, NCT04984226: Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD

Recruiting
2
80
US
Sodium bicarbonate, placebo
University of California, Davis, Vanderbilt University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Kidney Diseases, Metabolic Acidosis, Fatigue, Physical Endurance, Insulin Resistance, Mitochondrial Energetics, Diabetes
12/25
07/26
Oyegbile-Chidi, Temitayo
NCT05067634 / 2020-005344-27: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age with Partial-onset (focal) Seizures

Recruiting
3
140
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
05/26
07/26
Thai, Chinh
AIM HIGHer, NCT05064709: Assessment of CCM in HF with Higher Ejection Fraction

Recruiting
N/A
1500
US
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, CCM Group (CCM ON), OPTIMIZER™ Smart Mini System, Sham Group (CCM OFF)
Impulse Dynamics
Heart Failure, Heart Failure with Preserved Ejection Fraction, Heart Failure with Mid Range Ejection Fraction, Heart Failure with Moderately Reduced Ejection Fraction, Diastolic Heart Failure
02/25
02/26
Husen, Lilian Von
HOBIT, NCT02407028: Hyperbaric Oxygen Brain Injury Treatment Trial

Recruiting
2
200
Canada, US
Hyperbaric oxygen (1.5 ATA, no NBH), HBO, Hyperbaric oxygen (2.0 ATA, no NBH), Hyperbaric oxygen (2.5 ATA, no NBH), Hyperbaric oxygen (1.5 ATA + NBH), Hyperbaric oxygen (2.0 ATA + NBH), Hyperbaric oxygen (2.5 ATA + NBH), Normobaric Hyperoxia (NBH), NBH, Usual Care, Standard of Care
Hennepin Healthcare Research Institute, National Institute of Neurological Disorders and Stroke (NINDS), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network
Traumatic Brain Injury
10/26
06/27
NCT06131203: Burn Validation Study

Recruiting
N/A
240
US
DeepView SnapShot Portable (DV-SSP)
SpectralMD
Burns, Wound Heal, Wounds and Injuries
03/25
04/25
Hojman, Nayla
NCT06131203: Burn Validation Study

Recruiting
N/A
240
US
DeepView SnapShot Portable (DV-SSP)
SpectralMD
Burns, Wound Heal, Wounds and Injuries
03/25
04/25
Amezcua
OPTIS, NCT05566769: Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

Recruiting
N/A
103
Europe, US
NMOSDCopilot smartphone application
Ad scientiam
Neuromyelitis Optica
04/25
04/26
Lum, Zachary C
CHAT-OA, NCT06778486: Conversations in Health Literacy Using AI Technology for Osteoarthritis Patients

Not yet recruiting
N/A
100
US
Artificial Intelligence Chatbot
University of California, Davis
Osteoarthritis, Osteoarthritis of the Hip or Knee
10/25
10/25
 

Download Options